Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor protein p53, encoded by the TP53 gene, is a critical tumor suppressor that regulates cell division and prevents uncontrolled cell proliferation. It acts as a transcription factor, binding to DNA and activating genes involved in DNA repair, cell cycle arrest, apoptosis (programmed cell death), and other protective cellular responses. The Y220C mutation is a substitution of tyrosine with cysteine at position 220 within the DNA-binding domain. This mutation creates a hydrophobic cavity that destabilizes the protein, impairing DNA binding and tumor suppression. The unique surface cavity created by Y220C provides an opportunity for targeted drug design: small molecules can bind this crevice to stabilize mutant p53’s structure.
Small molecule stabilization of mutant protein structure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Protein p53 Y220C Mutant (p53 Y220C).